Insider Trading Alert - APOL, OPK And MMM Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Yesterday, Feb. 19, 2014, 110 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $21.54 to $422,568,000.00.

Highlighted Stocks Traded by Insiders:

Apollo Education Group (APOL) - FREE Research Report

Martin Sean who is SVP, General Counsel at Apollo Education Group sold 3,709 shares at $32.05 on Feb. 19, 2014. Following this transaction, the SVP, General Counsel owned 111,958 shares meaning that the stake was reduced by 3.21% with the 3,709-share transaction.

The shares most recently traded at $32.92, up $0.87, or 2.65% since the insider transaction. Historical insider transactions for Apollo Education Group go as follows:

  • 4-Week # shares sold: 3,795
  • 12-Week # shares sold: 70,108
  • 24-Week # shares sold: 105,704

The average volume for Apollo Education Group has been 2.4 million shares per day over the past 30 days. Apollo Education Group has a market cap of $3.7 billion and is part of the services sector and diversified services industry. Shares are up 20.75% year-to-date as of the close of trading on Wednesday.

Apollo Education Group, Inc., together with its subsidiaries, provides online and on-campus educational programs and services at the undergraduate, master's, and doctoral levels. The company has a P/E ratio of 17.6. Currently there are 2 analysts that rate Apollo Education Group a buy, 1 analyst rates it a sell, and 11 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on APOL - FREE

TheStreet Quant Ratings rates Apollo Education Group as a hold. The company's strengths can be seen in multiple areas, such as its solid stock price performance, largely solid financial position with reasonable debt levels by most measures and attractive valuation levels. However, as a counter to these strengths, we also find weaknesses including weak operating cash flow and feeble growth in the company's earnings per share. Get the full Apollo Education Group Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Opko Health (OPK) - FREE Research Report

Frost Phillip Md Et Al who is CEO & Chairman at Opko Health bought 20,900 shares at $8.68 on Feb. 19, 2014. Following this transaction, the CEO & Chairman owned 139.2 million shares meaning that the stake was reduced by 0.02% with the 20,900-share transaction.

The shares most recently traded at $8.40, down $0.28, or 3.38% since the insider transaction. Historical insider transactions for Opko Health go as follows:

  • 4-Week # shares bought: 20,000
  • 4-Week # shares sold: 46,730
  • 12-Week # shares bought: 30,000
  • 12-Week # shares sold: 46,730
  • 24-Week # shares bought: 30,000
  • 24-Week # shares sold: 46,730

The average volume for Opko Health has been 4.1 million shares per day over the past 30 days. Opko Health has a market cap of $3.5 billion and is part of the health care sector and health services industry. Shares are up 2.49% year-to-date as of the close of trading on Wednesday.

Opko Health, Inc., a pharmaceutical and diagnostics company, engages in the discovery, development, and commercialization of novel and proprietary technologies. It operates in two segments, Pharmaceuticals and Diagnostics. Currently there are 3 analysts that rate Opko Health a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on OPK - FREE

TheStreet Quant Ratings rates Opko Health as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures and expanding profit margins. However, as a counter to these strengths, we also find weaknesses including feeble growth in the company's earnings per share, deteriorating net income and weak operating cash flow. Get the full Opko Health Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

3M (MMM) - FREE Research Report

Shin Hak Cheol who is Exec Vice President at 3M sold 3,998 shares at $132.34 on Feb. 19, 2014. Following this transaction, the Exec Vice President owned 46,841 shares meaning that the stake was reduced by 7.86% with the 3,998-share transaction.

Little Frank R Jr. who is Executive Vice President at 3M sold 1,088 shares at $131.94 on Feb. 19, 2014. Following this transaction, the Executive Vice President owned 279 shares meaning that the stake was reduced by 79.59% with the 1,088-share transaction.

The shares most recently traded at $131.07, down $0.87, or 0.66% since the insider transaction. Historical insider transactions for 3M go as follows:

  • 4-Week # shares sold: 240
  • 12-Week # shares bought: 6,625
  • 12-Week # shares sold: 2,877
  • 24-Week # shares bought: 6,625
  • 24-Week # shares sold: 4,977

The average volume for 3M has been 3.3 million shares per day over the past 30 days. 3M has a market cap of $87.3 billion and is part of the industrial goods sector and industrial industry. Shares are down 6.91% year-to-date as of the close of trading on Wednesday.

3M Company operates as a diversified technology company worldwide. The stock currently has a dividend yield of 2.59%. The company has a P/E ratio of 19.6. Currently there are 7 analysts that rate 3M a buy, 1 analyst rates it a sell, and 5 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on MMM - FREE

TheStreet Quant Ratings rates 3M as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, growth in earnings per share, good cash flow from operations, solid stock price performance and expanding profit margins. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. Get the full 3M Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.
null

If you liked this article you might like

5 Things You Must Know Before the Market Opens Monday

5 Things You Must Know Before the Market Opens Monday

Week Ahead: Wall Street Welcomes Fourth-Quarter Earnings With the Big Banks

Week Ahead: Wall Street Welcomes Fourth-Quarter Earnings With the Big Banks

It's Going to Take More Than Lax Regulation to Turn Around For-Profit Education Sector

It's Going to Take More Than Lax Regulation to Turn Around For-Profit Education Sector

Buying Stocks With a Private Equity Mindset

Buying Stocks With a Private Equity Mindset

Private Equity: Elevated Valuations Warrant Elevated Caution

Private Equity: Elevated Valuations Warrant Elevated Caution